EUVIMEDEUVIMED entdecken
Crossref

Prognostic value of multiparameter [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer

Zeyu Zhang, Shiwei Guo, Weiwei Su, Guixia Pan, Yiting Wang, Yuchao Li, Kai Cao, Hui Jiang, Lu Zhang, Chao Cheng iD, Haojun Chen, Gang Jin und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07491-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Zeyu Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Biomarkers, Tumor, Magnetic Resonance Imaging, Positron-Emission Tomography. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission, Changhai Hospital of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: In this retrospective study, whether [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers can predict the progression-free survival (PFS) and overall survival (OS) of patients with advanced pancreatic cancer was investigated. METHODS: Fifty-one patients who underwent [68Ga]Ga-DOTA-FAPI-04 PET/MR scans before first-line chemotherapy were recruited. Imaging biomarkers, including the maximum tumor diameter, minimum apparent diffusion coefficient (ADC), maximum and mean standardized uptake values (SUVmax and SUVmean), fibroblast activation protein- (FAP-) positive tumor volume (FTV and W-FTV) and total lesion FAP expression (TLF and W-TLF), were recorded for primary and whole-body tumors. A subgroup analysis of 28 patients with obstructive inflammation was performed, and the maximum and mean standardized uptake values (D-SUVmax and D-SUVmean), FAP-positive uptake volume (D-FTV), and total FAP expression (D-TLF) in the distal pancreas were assessed. Kaplan-Meier analysis and the Cox proportional hazards model were used to assess the relationships between these imaging biomarkers and PFS/OS. RESULTS: SUVmax was negatively correlated with the ADC (r = -0.288, P = 0.041), whereas tumor length was positively correlated with the FTV, TLF, W-FTV, and W-TLF (r = 0.311-0.508, P 516.09 (P < 0.001). Univariate and multivariate Cox regression analyses identified W-TLF as an independent predictor of PFS (P = 0.001, hazard ratio (HR) = 4.949). The TNM stage, tumor length, ADC value, SUVmax, TLF, W-FTV, and W-TLF were significantly associated with OS (P < 0.05). Multivariate analysis further confirmed that tumor length, ADC, and W-TLF were independent predictors of OS (P < 0.05). A subgroup analysis including 28 patients with obstructive pancreatitis revealed that TNM stage, tumor length, W-FTV, W-TLF, D-FTV, and D-TLF were significantly associated with OS (P < 0.05). The multivariate analysis further identified W-TLF and D-FTV as independent predictors of OS (P < 0.05). CONCLUSIONS: [68Ga]Ga-DOTA-FAPI-04 PET/MRI biomarkers are associated with the PFS and OS of pancreatic cancer patients. Both the ADC and W-TLF are independent risk factors for patients with advanced disease. Increased fibroblast activity, driven by cancer-induced inflammation, may influence long-term survival outcomes following adjuvant therapy. These biomarkers have potential for guiding future clinical trials, enabling personalized treatment strategies, and ultimately improving the management and prognosis of patients with pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsBiomarkers, TumorMagnetic Resonance ImagingPositron-Emission TomographyMultimodal ImagingOrganometallic CompoundsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesPrognosisAdultAged, 80 and overQuinolines

Stichwörter der Autor:innen

Fibroblast activation proteinPET/MRPancreatic cancerPrognosis[68Ga]Ga-DOTA-FAPI-04

Substanzen

Biomarkers, TumorOrganometallic Compounds68Ga-FAPIQuinolines

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China.
  • Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Naval Medical University, 168 Changhai Road, Yang Pu District, Shanghai, 200433, China.
  • Department of Radiology, Naval Medical Center, Naval Medical University, Shanghai, 200050, China.
  • Department of Radiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
  • Department of Pathology, Changhai Hospital, Navy Medical University, Shanghai, 200433, China.
  • Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen Cancer CenterXiamen, 361003, China. leochen0821@foxmail.com.

ORCID-Profile: Chao Cheng

Förderung

  • National Natural Science Foundation of China
  • Shanghai Municipal Health Commission
  • Changhai Hospital of Shanghai

Zitieren

APA

Zhang, Z., Guo, S., Su, W., Pan, G., Wang, Y., Li, Y., Cao, K., Jiang, H., Zhang, L., Cheng, C., Chen, H., Jin, G., & Zuo, C. (2026). Prognostic value of multiparameter [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07491-w

Vancouver

Zhang Z, Guo S, Su W, Pan G, Wang Y, Li Y, et al. Prognostic value of multiparameter [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07491-w

BibTeX
@article{Zhang2026,
  author = {Zhang, Zeyu and Guo, Shiwei and Su, Weiwei and Pan, Guixia and Wang, Yiting and Li, Yuchao and Cao, Kai and Jiang, Hui and Zhang, Lu and Cheng, Chao and Chen, Haojun and Jin, Gang and Zuo, Changjing},
  title = {Prognostic value of multiparameter [68Ga]Ga-DOTA-FAPI-04 PET/MR imaging biomarkers for patients with advanced pancreatic cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07491-w}
}
Kostenlos starten →